Mankind Pharma Ltd. has announced the appointment of Dr. Tausif Ahmed as its Senior Vice President & Head of Clinical Research and Biopharmaceutics, further strengthening its leadership team in the areas of drug development, bioequivalence, and clinical research.

With a career spanning over 24 years in the pharmaceutical sector, Dr. Ahmed brings deep expertise in clinical pharmacokinetics, bioequivalence studies, biopharmaceutics, and advanced modelling & simulation strategies. His professional journey covers senior roles at leading organisations such as Dr. Reddy’s Laboratories, Piramal Group, Sai Life Sciences, Sun Pharma, and Aizant Drug Research Solutions, before taking up this leadership role at Mankind Pharma in July 2025.

Dr. Ahmed has played a pivotal role in shaping clinico-regulatory strategies for complex generics, biosimilars, differentiated formulations (505b2), peptides, depot injectables, nanoparticles, and liposomal drugs. He is widely recognised for his expertise in PBPK/PBBM modelling, IVIVC, and dissolution safe space approaches, which have helped improve bio-confidence in global regulatory submissions.

Over the course of his career, Dr. Ahmed has:

• Filed more than 20 INDs for NCEs in the US and over 300 ANDAs for various markets.
• Collaborated with leading regulatory authorities, including the USFDA, EMA, ANVISA, NPRA Malaysia, and CDE China.
• Published over 60 manuscripts and contributed to international conferences, while serving as a reviewer for reputed scientific journals.
• Partnered with institutions like Johns Hopkins Cancer Institute and Joslin Diabetes Centre, Boston, for therapeutic advancements in oncology and diabetes.

An alumnus of NIPER, Mohali (MS Pharm) and a Ph.D. in Pharmaceutical Medicine from Jamia Hamdard-Ranbaxy collaboration, Dr. Ahmed has been instrumental in building strategies around bioequivalence studies, regulatory compliance, and innovative clinical designs for complex generics and NCEs.

Also read: Canon Medical Systems India Partners with Rajiv Gandhi Cancer Institute to Advance Cancer Diagnostics

His appointment is expected to bolster Mankind Pharma’s R&D and clinical research capabilities, particularly as the company expands its portfolio in biosimilars, differentiated products, and advanced generics for global markets.

Like

Dislike

Be a part of Elets Collaborative Initiatives. Join Us for Upcoming Events and explore business opportunities. Like us on Facebook , connect with us on LinkedIn and follow us on Twitter , Instagram.

"Exciting news! Elets technomedia is now on WhatsApp Channels Subscribe today by clicking the link and stay updated with the latest insights!" Click here!